דלג לתוכן הראשי
Zombie Cells

Vanadyl Sulfate: A Supplement That Clears Zombie Cells in Mice

A new University of Chicago study in Nature Aging found that vanadyl sulfate, a mineral sold as a dietary supplement, selectively kills zombie (senescent) cells in cell cultures and extends the lifespan of older male mice. But the groups were small, the difference barely reached significance, females were not tested, and there is no human trial. Here is the mechanism, the evidence, and why this is still no reason to rush to the store.

⏱️25 Reading minutes ✍️Nir Nagar 👁️1 Views

In the world of senolytics, the hunt for the perfect drug usually looks like an expensive expedition: libraries of thousands of molecules, cancer drugs repurposed for new uses, and complex attempts to engineer custom biological tools. But sometimes the answer hides in the least expected place: on the shelf of a supplement store.

On November 6, 2026, a group from the University of Chicago, led by Dr. Jing Chen, published a paper in Nature Aging pointing to an unexpected candidate: vanadyl sulfate, a mineral sold as a dietary supplement. In cell and mouse experiments it was found to selectively kill zombie cells, and about three months of treatment in old age increased the lifespan of male mice. It is an attractive headline, and precisely for that reason it is worth reading slowly: what was tested, in which population, and what is still unknown.

This story is interesting less because it is "yet another supplement that extends life in mice" and more because of the way it works. It does not attack the classic survival mechanism of zombie cells, but exploits a chemical burden that these cells already carry. And even that, as we will see, is still very far from a recommendation to buy the bottle.

What is vanadyl sulfate?

Vanadyl sulfate (chemical formula VOSO4) is a salt of vanadium, a trace metal. It is not a new molecule or an experimental drug, but a familiar substance sold as a supplement. What is new is its biological interpretation.

  • An existing supplement on the market: a mineral sold without a prescription, which the paper describes as a "mineral dietary supplement."
  • A finding that came from screening: the researchers screened a library of compounds to find substances that eliminate aging cells, and vanadyl sulfate emerged as an unexpected candidate.
  • Selectively kills senescent cells: in cell culture, senescent cells responded to it strongly, while non-senescent cells responded much less.
  • Acts as a gentle oxidant: it behaves as a "mild oxidant," and this property is what undermines the old cells.
  • Not an approved longevity drug: it has no such indication, and no human trial has tested it for this purpose.

The field called senolytics deals with drugs that eliminate zombie cells: cells that have stopped dividing but do not die, and secrete inflammatory substances that harm the surrounding tissue. Vanadyl sulfate now joins the list of candidates, with a mechanism different from the familiar ones.

How does it work? Mechanism: when proteins fold incorrectly

To understand the finding you need to know a small chemical detail: cysteine, one of the amino acids that build proteins. Cysteine has a reactive sulfur group, and it can bind to another cysteine to form a disulfide bridge. These bridges are like pins that hold the protein in its correct three-dimensional shape. Many proteins, especially those the cell secretes outward, fold inside the endoplasmic reticulum (ER), the cell's "protein factory." There a team of folding enzymes, including PDI and ERO1α, handles the formation and repair of disulfide bridges.

What the researchers found is that senescent cells have a distinctive cysteine profile. In senescent cells and in aged tissues there was an overall decrease in the "cysteine reactivity" of proteins, alongside an increase in the expression and cysteine reactivity of ER folding proteins. Among 98 proteins that showed increased cysteine reactivity, both in senescent cells and in cells treated with GSSG (the oxidized form of glutathione), folding proteins such as ERO1α and PDI were significantly enriched.

In simple terms: a zombie cell is already under strain in its "factory," and its folding proteins are working at the limit. When vanadyl sulfate is added, the mild oxidant pushes even further toward the formation of disulfide bridges. Healthy cells maintain enough reducing capacity to cope with this. Zombie cells less so. The result, according to the paper, is protein misfolding, aggregation, and the formation of improper disulfide bridges, and finally programmed cell death (apoptosis).

Why are zombie cells specifically vulnerable to this?

The paper points to a combination of two things: cysteines that are already more "occupied" in the old cells, and an increased load on the folding proteins. There is another plausible biological explanation here, which is general context and not a finding of the paper: zombie cells produce and secrete large amounts of proteins (this is the SASP, their inflammatory cocktail), so their ER works especially hard. A system already working at the edge of its capacity is more sensitive to a small disturbance. But it is important to stress that this is an explanatory hypothesis, not proof.

What did they test to show this is indeed the mechanism?

The team did not settle for a nice description, and ran several tests that strengthen the explanation:

  • Aggregates accumulating only in old cells: vanadyl sulfate caused selective accumulation of clumped proteins in senescent cells.
  • Inhibiting the cleanup system worsened the effect: blocking the mechanism that removes damaged proteins increased the supplement's senolytic effect, while strengthening this mechanism restored some of the cells' viability.
  • Fixing the chemistry restores reactivity: NAC (N-acetyl-cysteine, a molecule with its own sulfur group) restored cysteine reactivity in senescent cells, while Trolox, a different type of antioxidant, did not. This suggests the story is about specific cysteine chemistry, and not about "oxidation" in general.

Note a subtle point: this substance acts in the opposite direction from what we would expect of a classic "health supplement." Here it does not act as a classic antioxidant that protects cells: according to the paper it disables reactive cysteines and promotes disulfide bridge formation, exploiting the fact that zombie cells accumulate oxidized glutathione (GSSG) because of reduced glutathione reductase enzyme. This is further proof that senolytics are not a "cleansing supplement", but a chemical intervention with thin borders between harming the diseased cell and harming the healthy one.

The general background: what happens when the ER comes under stress?

Cells have a quality control system for proteins, which identifies proteins that did not fold properly and tries to repair or degrade them. When the load exceeds capacity, the cell enters a state called endoplasmic reticulum stress, and in extreme cases a programmed cell death pathway is activated. This is a general and well-known mechanism in cell biology, and it provides a plausible context for the finding: if a zombie cell is already approaching the limit of its folding system's capacity, one more gentle push toward incorrect disulfide bridges may be enough to tip it over. Healthy cells, with a larger reserve, survive the same push. The researchers described exactly this: disrupted protein handling, and death by apoptosis, in senescent cells.

What remains open is how much of this effect really happens in a living body, and in which tissues. Cell cultures show that the mechanism is possible, and the mouse experiments show a generally positive outcome, but direct measurement of how many senescent cells disappeared from each tissue, and the causal link between their removal and the lifespan extension, are the link that still needs strengthening.

Why does clearing senescent cells matter at all?

Cellular senescence is originally a defense mechanism: a cell with DNA damage or other worrying signs "hits the brakes" and stops dividing, reducing the risk that it will become cancerous. In youth, the immune system clears these cells efficiently. With the years they accumulate, and because of the SASP they secrete they can contribute to chronic inflammation in the tissue. This is why so many labs are looking for ways to clear them. As Dr. Chen noted in the university's announcement, if such cells are not cleared or accumulate beyond the clearance capacity, they may lead to inflammation and worsen aging.

But there is an inherent difficulty here: senescence is also a useful biological tool, so an ideal senolytic must harm the damaging cells and not those that play a positive role. This is why selectivity, that is, the ability to distinguish between cell types, is the point where most candidates fail on the way from the lab to the clinic.

The current evidence

Before diving into the studies, it is worth understanding how such evidence is ranked. A finding in cell culture is the weakest level in terms of relevance to humans: it shows a biological possibility, not a result in a living body. A mouse experiment is a step forward, but rodents differ from us in metabolism, lifespan, and response to drugs. Only controlled clinical trials in humans can answer whether something works and is safe. As of today, vanadyl sulfate as a senolytic is at the level of cells and mice only.

Study 1: Lifespan extension in male mice, Nature Aging 2026

The main study was conducted at the University of Chicago and published in Nature Aging (volume 6, pages 2469-2492). According to the Lifespan Research Institute's report on the paper, a 90-day treatment begun in male mice aged about 71 weeks (old age) raised median lifespan from 887 to 952 days, an increase of 7.4%. That is about 65 additional days in the median.

The data look impressive, but they come with an important frame. The groups were small, about 20 mice per group, and the difference in lifespan barely reached statistical significance. In addition, female lifespan was not tested. The paper itself notes that the effect on lifespan in females, as well as the mechanism behind the lifespan extension in males, are still unknown. That is, there is no proof that the lifespan extension stemmed specifically from clearing zombie cells, even if that is the natural hypothesis. The Lifespan.io report also notes, regarding an experiment in which treatment was stopped and the improvements in fitness and metabolic measures persisted, that the results are consistent with a lasting change in tissue composition, such as removal of senescent cells, but do not prove it.

Two notes on reading the number correctly. First, "median lifespan" is the age at which half of the mice in the group are still alive, and it differs from "maximum lifespan." An increase in the median shows that the group as a whole lived longer, but not necessarily that the longest-lived mice lived much longer. Second, 7.4% in mice is a number that cannot be translated into years in humans: there is no reliable way to say "this would be a few years in a person."

The experimental dose also matters: in the older mice, vanadyl sulfate was given in drinking water, at a concentration of 0.15 mg per mL, for 13 weeks. This concentration should not be translated into a human dose.

Study 2: Cell experiments and cysteine mapping, Nature Aging 2026

The biochemical part of the same paper was done mainly in cell cultures, including BJ cells (a human fibroblast cell line) induced into senescence. The researchers used a gel-based method called ABPP (activity-based protein profiling) to map which cysteines remain reactive. The main finding: vanadyl sulfate further reduced cysteine reactivity in senescent cells, but barely affected non-aging cells.

The importance here is twofold. First, it is a demonstration that the substance kills selectively, which is at the heart of any good senolytic. Second, the researchers present the combination of generally low cysteine reactivity together with high expression of ER folding proteins as a new feature of senescent cells that had not been identified before. Even if vanadyl sulfate never reaches the clinic, the discovery may serve as a basis for more precise drugs.

Study 3 (same paper): Improvement in aging signs and age-related diseases in mice, Nature Aging 2026

According to the paper, male mice aged 76 weeks that received vanadyl sulfate in drinking water for 13 weeks showed improvement in common signs of aging, and similar improvements were seen in a separate experiment in which the substance was given directly by mouth three times a week for four weeks. Overall, the researchers reported relief of the effects of chronic age-related diseases, including diabetes, heart disease and liver disease, in mice. The paper notes that improvement in aging phenotypes was seen in both sexes, even though the effect on lifespan was tested only in males.

It is important to understand what this means and what it does not: these are mouse models, and "improvement in signs" is not equivalent to "curing a disease." The measures reflect conditions in mice, not clinical outcomes in humans. In addition, vanadium has been known for years to affect blood sugar regulation, so when an improvement in metabolic measures is seen, it is hard to know how much of it stems from clearing zombie cells and how much from the substance's direct metabolic effect.

Study 4: Vanadyl sulfate in humans with type 2 diabetes, a small trial unrelated to senolytics

A clarification is needed here: there is currently no human study that tested vanadyl sulfate as a senolytic. What does exist is relatively old literature on vanadyl sulfate as a possible diabetes drug. In one trial, 16 patients with type 2 diabetes were treated for 6 weeks at three different doses. The researchers reported that doses of 150 and 300 mg caused gastrointestinal discomfort. A later review notes that the main side effects in trials of this type were nausea and mild diarrhea in some participants.

This information matters not because it proves anything about lifespan extension, but because it shows what a "therapeutic dose" of vanadyl sulfate looks like in humans, and that it is already in the range that causes side effects. More on this in the criticism section.

The broader perspective: what else changes here?

This finding fits into a larger picture of the field. Many of the familiar senolytic candidates rely on attacking the survival mechanisms of the old cell. Here it is a different approach: exploiting the folding and redox burden of the old cell itself. If this approach is replicated in other labs, it will add a new "vulnerability axis" to the list, and will allow considering combinations of different mechanisms in the future.

There is also a methodological lesson here. Vanadyl sulfate was discovered because a library of compounds was searched, not because someone guessed it would work. This is a reminder that good candidates can hide among "old and familiar" substances, but also that only a controlled experiment, and not anecdotes, can tell a promise from marketing.

The researchers report that they are now working with chemists on new formulations of vanadyl sulfate that will improve its potency and its delivery to cells, with the aim of testing them in additional animal disease models, and perhaps in the future also in human clinical trials, as an addition to existing treatments. That is, even the authors themselves see the existing product as a starting point, not a final product.

And finally, we cannot ignore the broad connection to a story that recurs on this site again and again: not every zombie cell is the same, and not every senolytic suits every tissue. That is, even if vanadyl sulfate works well on one type of senescent cell, we still have no information about its effect on senescent cells that play a beneficial role, for example in wound healing.

Another point worth noting is the idea of short, non-continuous treatment. Zombie cells accumulate slowly, so in the senolytics field it is customary to think of treatment in short pulses rather than continuous daily intake. In the current study too, vanadyl sulfate was given for a span of weeks to three months in old age. However, the paper itself does not determine an optimal treatment plan, so no prescription of any kind should be inferred from it.

Last but not least: the finding is a reminder that the line between "antioxidant" and "oxidant" is not always sharp. In popular culture antioxidants are seen as necessarily good, but in cell biology the level and location of oxidation determine everything. Controlled oxidative stress can serve as a signal, and sometimes also as a tool. Such a mechanism requires a precise dose, not another supplement taken "just in case."

Should you start taking vanadyl sulfate?

The short answer: not on the basis of this study. The following list explains why.

  • The data are from mice, and mainly from males: lifespan was examined only in males, in groups of about 20 mice, and the difference barely reached significance. Mice are not humans, and lifespan extension results in rodents do not always translate to humans.
  • The mechanism behind the lifespan extension has not been proven: the paper itself says the mechanism behind lifespan extension in males is unknown. Other mechanisms may contribute, not only the clearing of zombie cells.
  • No human trial with a senolytic aim: it is not known what dose, if any, clears zombie cells in humans, and whether it does so safely.
  • Known human doses come with side effects: in diabetes trials, doses of 150-300 mg caused digestive discomfort.
  • A narrow safety margin: according to the information site RxList, the tolerable upper intake level (UL) for vanadium is 1.8 mg per day of elemental vanadium. A dose of 100 mg vanadyl sulfate, studied in diabetes, contains about 31 mg of elemental vanadium, roughly 17 times that limit. The site also warns that such high doses, in long-term use, may not be safe.
  • Interaction with diabetes drugs: vanadium may lower blood sugar levels, so combining it with diabetes drugs may cause excessive drops.
  • Supplement quality varies: supplements are not subject to oversight similar to that of drugs, and the content of a capsule is not always identical to what is written on the label.

One more point: in mice, a short, time-limited treatment in old age was tested, not daily intake for life. The translation to "I'll take it every day" is exactly the opposite of the model that was studied, and has no support whatsoever. And even if it turns out in the future that such an approach works, it is likely to require a formulation and dose determined in trials, and not independent use of a supplement sold today.

Why is a "supplement" not the same as a "drug"?

The word "supplement" creates a sense of security: something natural, available, sold in a store. But the mere fact that a substance is sold as a supplement does not mean its safety was tested at the dose and duration required for a new purpose. Vanadyl sulfate is a good example: it is sold mainly in other contexts, and the doses studied in humans were aimed at improving blood sugar regulation, not at affecting zombie cells. We have no data showing that the same dose, or a lower one, acts on senescent cells in a human body, and there is no guarantee that the supplement on the shelf contains the same amount as was given in the experiment.

There is also a question of symmetry: a mechanism that relies on controlled oxidative stress may be sensitive to a person's reductive state, that is, to the cells' ability to absorb oxidants. In people with underlying diseases or a different diet, we have no information on how this will behave. This is not evidence that there is a problem, but a reminder of the number of open questions that remain.

What does the next step look like?

For this story to progress beyond the headline, several steps are missing. Replication of the results in an independent lab, with larger groups and with females, will answer whether the lifespan extension is real and stable. Safety and toxicology studies will determine whether there is a dose that clears zombie cells without harming other tissues. Mechanism studies will examine whether the lifespan extension indeed stems from the removal of senescent cells. And only after all of these, a small clinical trial in humans will be able to ask whether the old cells indeed decrease, and whether there is an improvement in function. Until then, this is a promising hypothesis and nothing more.

Questions readers typically ask

Does the study prove the supplement extends life? No. It shows a moderate increase in the median lifespan of male mice, in small groups, barely statistically significant. It is an interesting sign that justifies further testing, not proof.

Does this mean female mice would benefit similarly? Unknown. Female lifespan was not tested, although improvements in aging signs were seen in both sexes.

Is the effect due to clearing zombie cells? That is the leading explanation, and it is supported by the cell experiments, but the paper notes that the mechanism behind the lifespan extension in males has not yet been determined.

Should someone currently taking vanadium for blood sugar stop? That is a question for the treating physician, not for an article. The information here is no substitute for medical consultation, and treatment should certainly not be stopped or changed without consulting.

What should you take from the study?

  1. Don't rush to the store: do not start taking vanadyl sulfate or vanadium on the assumption that it is a proven senolytic. If you are considering any supplement, especially if you take medications or have diabetes, kidney disease or liver disease, consult a doctor first.
  2. Read headlines about a "life-extending supplement" critically: check whether the study was done in mice or humans, how many animals were in the group, of which sex, and whether the result is statistically significant.
  3. Understand that senolytics is a field in the making: the paper's great value is a new understanding of the vulnerability of zombie cells, not a supplement ready for use.
  4. Lean on what has been studied in humans: physical activity, good sleep, balanced nutrition and control of blood sugar and blood pressure are the foundation of healthy aging, and do not require taking an experimental mineral.
  5. Follow the continuing research: it is worth waiting for replication of the results in independent labs, testing in females, and the new formulations the researchers are developing.

The broader perspective

The vanadyl sulfate story is a reminder that in the aging field, the road from "works in a mouse" to "safe and effective in a human" is longer than the headlines hint. The study is fascinating because it reveals a real chemical weakness of zombie cells: they rely on a protein-folding machine that is already at the edge, and it can be pushed over the edge. This is an insight into biology, and it is worth more than any bottle in a store.

Even if vanadyl sulfate itself never reaches the clinic, the understanding that aging cells differ from young cells in the chemistry of their proteins opens a door to more precise drugs. A supplement that clears old cells in a mouse is an opening to a question, not an answer, and sometimes the smartest move in science is to wait for the evidence before touching the button.

References:
Wu R. et al., Altered protein cysteine reactivity in senescent cells is a vulnerability for senolysis to ameliorate aging, Nature Aging 2026
Lifespan Research Institute: A Supplement Kills Senescent Cells and Extends Life in Mice

ניר נגר

Nir Nagar

Nir Nagar, founder and editor of Reverse Aging and a biohacker with over 20 years of hands-on experience in longevity research, supplements, and health optimization. He researches every topic in depth before publishing, honestly grades the strength of the evidence, and links to the original studies in every article.

Full profile ↗

Sources and citations

💬 Comments (0)

To respond, you need an account. Write your response and click publish, and you will be taken to a quick registration. The response will be saved and published after approval.

Be the first to comment on the article.

Did you enjoy the site? Tell your friends 🙌 Didn't enjoy it? Tell us and we'll improve 💬

💬 Tell us